BR112022001674A2 - Composição farmacêutica para administração por via otológica - Google Patents

Composição farmacêutica para administração por via otológica

Info

Publication number
BR112022001674A2
BR112022001674A2 BR112022001674A BR112022001674A BR112022001674A2 BR 112022001674 A2 BR112022001674 A2 BR 112022001674A2 BR 112022001674 A BR112022001674 A BR 112022001674A BR 112022001674 A BR112022001674 A BR 112022001674A BR 112022001674 A2 BR112022001674 A2 BR 112022001674A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
otological
administration
mpa
ear
Prior art date
Application number
BR112022001674A
Other languages
English (en)
Inventor
Akira Nagakura
Hiroyuki Kojima
Ken Shimada
Mari Osada
Takatsune Yoshida
Takaya Matsuda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112022001674A2 publication Critical patent/BR112022001674A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica para administração por via otológica. a presente invenção refere-se a uma composição farmacêutica que pode ser administrada no ouvido sem nenhuma operação complicada e tem a função de permitir que um fármaco seja retido e lentamente liberado no ouvido. a composição farmacêutica para administração por via otológica, compreende um, dois ou mais fármacos e um polímero, em que quando a viscosidade complexa da composição farmacêutica é medida usando um reômetro sob as condições de uma tensão de cisalhamento de 5% e uma frequência angular de 50 rad / s, enquanto aumenta a temperatura de 25º c para 37º c a uma taxa de aquecimento de 1º c / 10 s, a viscosidade complexa é inferior a 1.650 mpa.s a 25º c, e é de 1.650 mpa.s a 100.000 mpa.s em 10 minutos após atingir 37º c.
BR112022001674A 2019-07-31 2020-07-30 Composição farmacêutica para administração por via otológica BR112022001674A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019140977 2019-07-31
PCT/JP2020/029342 WO2021020535A1 (ja) 2019-07-31 2020-07-30 耳内投与用の医薬組成物

Publications (1)

Publication Number Publication Date
BR112022001674A2 true BR112022001674A2 (pt) 2022-03-22

Family

ID=74228876

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001674A BR112022001674A2 (pt) 2019-07-31 2020-07-30 Composição farmacêutica para administração por via otológica

Country Status (11)

Country Link
US (1) US20230157946A1 (pt)
EP (1) EP4008353A4 (pt)
JP (1) JPWO2021020535A1 (pt)
KR (1) KR20220041143A (pt)
CN (1) CN114222589A (pt)
AU (1) AU2020319755A1 (pt)
BR (1) BR112022001674A2 (pt)
CA (1) CA3148042A1 (pt)
MX (1) MX2022001374A (pt)
TW (1) TW202120126A (pt)
WO (1) WO2021020535A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202107976D0 (en) * 2021-06-03 2021-07-21 Norbrook Lab Ltd Sol-gel compositions for veterinary use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001247410B2 (en) 2000-03-14 2005-05-12 Alcon, Inc. Viscoelastics for use in middle ear surgery
WO2008124467A1 (en) 2007-04-06 2008-10-16 Macrocyclics Bifunctional hydroxamic acid ligands and method of synthesis
EP3508197A1 (en) * 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―，インク． ポロクサマーを包含する製剤のゲル化温度の調節
PT2996709T (pt) 2013-05-15 2020-07-14 Univ Leland Stanford Junior Modulação da atividade do fator de crescimento epidérmico de ligação à heparina para cicatrização da membrana timpânica
US20180071209A1 (en) * 2015-03-24 2018-03-15 Dow Global Technologies Llc Aqueous solution of polymers
CN105769753B (zh) * 2016-04-19 2019-10-29 浙江工业大学 一种温敏凝胶基质及其制备方法与应用
EP3554508A4 (en) * 2016-12-19 2020-08-05 Druggability Technologies IP Holdco Limited SUVOREXANT PHARMACEUTICAL FORMULATIONS

Also Published As

Publication number Publication date
JPWO2021020535A1 (pt) 2021-02-04
MX2022001374A (es) 2022-03-17
EP4008353A4 (en) 2023-05-10
WO2021020535A1 (ja) 2021-02-04
US20230157946A1 (en) 2023-05-25
TW202120126A (zh) 2021-06-01
KR20220041143A (ko) 2022-03-31
CA3148042A1 (en) 2021-02-04
EP4008353A1 (en) 2022-06-08
CN114222589A (zh) 2022-03-22
AU2020319755A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
HRP20230709T1 (hr) Farmaceutski pripravci za liječenje bolesti povezanih s regulatorom provodljivosti transmembrane cistične fibroze
BR112018010018A2 (pt) moduladores de ror-gama
MX2019014122A (es) Formulaciones de dosis fija.
BR112018076114A2 (pt) composições tópicas de apremilast
BR112018002227A2 (pt) composições com potencializadores de permeação para administração de fármaco
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
BR112015026418A2 (pt) formulação de liberação prolongada da colchicina como ingrediente ativo, método para o tratamento e/ou prevenção de uma doença cardiovascular ou uma doença inflamatória em um indivíduo, processo de preparação de um comprimido de liberação prolongada da colchicina e composição terapêutica de liberação prolongada moldada e comprimida compreendendo a colchicina e excipientes combinados em uma matriz
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018001584A (es) Composiciones de solución sólida para aines.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112013013123A2 (pt) dispositivo de entrega de fármaco
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
BR112022001674A2 (pt) Composição farmacêutica para administração por via otológica
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
WO2016040814A3 (en) Disulfide polymers and methods of use
WO2016040462A3 (en) Formulations and methods for treatment of metabolic syndrome
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물